[
    [
        {
            "time": "2018-01-02",
            "original_text": "AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Advancing",
                    "Solid Tumor",
                    "Portfolio"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "5 Ways Gilead Sciences Plans to Return to Growth",
            "features": {
                "keywords": [
                    "Gilead",
                    "Sciences",
                    "Return",
                    "Growth"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "5 Ways Gilead Sciences Plans to Return to Growth",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Notable Tuesday Option Activity: MCK, ABBV, BIIB",
            "features": {
                "keywords": [
                    "Option",
                    "Activity",
                    "MCK",
                    "ABBV",
                    "BIIB"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Notable Tuesday Option Activity: MCK, ABBV, BIIB",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie's Upadacitinib Gains Breakthrough Therapy Designation",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Upadacitinib",
                    "Breakthrough",
                    "Therapy",
                    "Designation"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie's Upadacitinib Gains Breakthrough Therapy Designation",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Is AbbVie Stock Still A Strong Buy?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Stock",
                    "Strong",
                    "Buy"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is AbbVie Stock Still A Strong Buy?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie’s Venclexta for Chronic Lymphocytic Leukemia",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Venclexta",
                    "Chronic",
                    "Lymphocytic",
                    "Leukemia"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie’s Venclexta for Chronic Lymphocytic Leukemia",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie Expects Peak Sales of $7 Billion for Imbruvica",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Peak",
                    "Sales",
                    "Imbruvica"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Expects Peak Sales of $7 Billion for Imbruvica",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "4 Best Marijuana Stocks to Play the Green Rush",
            "features": {
                "keywords": [
                    "Marijuana",
                    "Stocks",
                    "Green",
                    "Rush"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "cannabis"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "4 Best Marijuana Stocks to Play the Green Rush",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie's JAK1 Inhibitor Granted FDA's Breakthrough Therapy",
            "features": {
                "keywords": [
                    "AbbVie",
                    "JAK1",
                    "Inhibitor",
                    "FDA",
                    "Breakthrough",
                    "Therapy"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie's JAK1 Inhibitor Granted FDA's Breakthrough Therapy",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories",
            "features": {
                "keywords": [
                    "Ex-Dividend",
                    "Patterson",
                    "Companies",
                    "AbbVie",
                    "Abbott",
                    "Laboratories"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Risankizumab",
                    "Label",
                    "Immunology",
                    "Indications"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "See what the IHS Markit Score report has to say about AbbVie Inc.",
            "features": {
                "keywords": [
                    "IHS",
                    "Markit",
                    "Score",
                    "report",
                    "AbbVie"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "See what the IHS Markit Score report has to say about AbbVie Inc.",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Cramer's lightning round: Mercadolibre is even better tha...",
            "features": {
                "keywords": [
                    "Cramer",
                    "lightning",
                    "round",
                    "Mercadolibre"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Cramer's lightning round: Mercadolibre is even better tha...",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]